Leaflet: information for the user
ORVATEZ 10mg/20mg film-coated tablets
ORVATEZ 10mg/40mg film-coated tablets
ORVATEZ 10mg/80mg film-coated tablets
ezetimiba/atorvastatina
(ezetimibe/atorvastatin)
Read this leaflet carefully before you start to take this medicine, because it contains important information for you.
6. Contents of the pack and additional information
ORVATEZ is a medication that decreases high levels of cholesterol. ORVATEZ contains ezetimiba and atorvastatina.
ORVATEZ is used in adults to decrease levels of total cholesterol, "bad" cholesterol (low-density lipoprotein or LDL cholesterol), and certain fatty substances called triglycerides that circulate in the blood..Additionally, ORVATEZ increases concentrations of "good" cholesterol (high-density lipoprotein or HDL cholesterol).
ORVATEZ acts by reducing cholesterol in two ways. It reduces the cholesterol absorbed in the digestive tract, as well as the cholesterol that your body produces on its own.
Cholesterol is one of the fatty substances that are found in the circulatory system..Your total cholesterol is composed mainly of LDL and HDL cholesterol.
LDL cholesterol is often referred to as "bad" cholesterol because it can accumulate in the walls of your arteries, forming plaques. Over time, this accumulation of plaque can cause a narrowing of the arteries. This narrowing can make blood flow to vital organs such as the heart and brain slower or interrupted. This interruption of blood flow can trigger a heart attack or stroke..
HDL cholesterol is often referred to as "good" cholesterol because it helps prevent bad cholesterol from accumulating in the arteries and protects them from cardiovascular diseases..
Triglycerides are another type of fat present in your blood that can increase the risk of heart disease..
ORVATEZ is used in patients who cannot control their cholesterol levels solely with diet. While taking this medication, you should follow a cholesterol-lowering diet..
ORVATEZ is used, along with a cholesterol-lowering diet,if you have:
ORVATEZ does not help you lose weight.
Warnings and precautions
Consult your doctor or pharmacist before starting to take ORVATEZ.
Contact your doctor as soon as possible if you experience unexplained muscle pain, sensitivity, or muscle weakness while taking ORVATEZ.This is because, in rare cases, muscle problems can be severe, including muscle rupture causing kidney damage.It is known that atorvastatin causes muscle problems, and muscle problems have also been reported with ezetimibe.
Also inform your doctor or pharmacist if you experience persistent muscle weakness. Further tests and additional medicines may be needed to diagnose and treat this problem.
Consult your doctor or pharmacist before starting to take ORVATEZ:
If you are in any of the above circumstances (or are unsure), consult your doctor before starting to take ORVATEZ, as your doctor will need to perform a blood test before starting your treatment with ORVATEZ, and possibly during it, to predict the risk of experiencing muscle side effects. It is known that the risk of experiencing muscle side effects, e.g., rhabdomyolysis, increases when certain medicines are taken simultaneously (see section 2 “Taking ORVATEZ with other medicines”).
While you are taking this medicine, your doctor will monitor whether you have diabetes or are at risk of developing diabetes. This risk of diabetes increases if you have high levels of sugar and fat in your blood, obesity, and high blood pressure.
Inform your doctor of all your medical problems, including allergies.
You should avoid the combined use of ORVATEZ and fibrates (certain medicines for lowering cholesterol), as the combined use of ORVATEZ and fibrates has not been studied.
Children
ORVATEZ is not recommended for children and adolescents.
Taking ORVATEZ with other medicines
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine, including over-the-counter medicines.
There are some medicines that may modify the effect of ORVATEZ or whose effects may be affected by ORVATEZ (see section 3). This type of interaction may reduce the effectiveness of one or both medicines. On the other hand, it may also increase the risk or severity of side effects, including a serious condition in which muscle is destroyed, known as “rhabdomyolysis”, which is described in section 4:
** If you need to take fusidic acid orally to treat a bacterial infection, you will temporarily need to stop taking this medicine. Your doctor will tell you when you can restart your treatment with ORVATEZ. The use of ORVATEZ with fusidic acid rarely may cause muscle weakness, sensitivity, or pain (rhabdomyolysis). For more information on rhabdomyolysis, see section 4.
Taking ORVATEZ with food and alcohol
See section 3 for instructions on how to take ORVATEZ. Please note the following:
Orange juice
Do not take more than one or two small glasses of orange juice per day, as large amounts of orange juice may alter the effects of ORVATEZ.
Alcohol
Avoid excessive alcohol consumption while taking this medicine. For more details, see section 2 “Warnings and precautions”.
Pregnancy and breastfeeding
Do not take ORVATEZ if you are pregnant, trying to become pregnant, or breastfeeding.
Do not take ORVATEZ if you may become pregnant, unless you are using reliable contraceptive methods. If you become pregnant while taking ORVATEZ, stop taking it immediately and inform your doctor.
Do not take ORVATEZ if you are breastfeeding.
ORVATEZ has not been proven to be safe during pregnancy and breastfeeding.
Consult your doctor or pharmacist before taking this medicine.
Driving and operating machinery
ORVATEZ is not expected to interfere with your ability to drive or operate machinery. However, some people may experience dizziness after taking ORVATEZ.
ORVATEZ contains lactose
ORVATEZ tablets contain a sugar called lactose. If your doctor has told you that you have an intolerance to certain sugars, consult your doctor before taking this medicine.
ORVATEZ contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; that is, it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor. Your doctor will determine the appropriate dose per tablet for you, depending on your current treatment and personal risk situation. In case of doubt, consult your doctor or pharmacist again.
How much to take
The recommended dose is one ORVATEZ tablet once a day taken orally.
Administration form
Take ORVATEZ at any time of the day. You can take it with or without food.
If your doctor has prescribed ORVATEZ along with cholestyramine or any other bile acid sequestrant (medications that reduce cholesterol levels), you must take ORVATEZ at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If you take more ORVATEZ than you should
Consult your doctor or pharmacist.
If you forgot to take ORVATEZ
Do not take an extra dose; the next day, take your normal amount of ORVATEZ at the usual time.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
If you experience any of the following serious side effects or symptoms, stop taking your tablets and immediately inform your doctor, or go to the nearest hospital emergency department.
Consult your doctor as soon as possible if you experience problems associated with the unexpected or unusual appearance of bleeding or bruising, as this may be indicative of liver disease.
The following side effects were frequently reported (may affect up to 1 in 10 patients):
The following side effects were infrequently reported (may affect up to 1 in 100 patients):
The following side effects were reported with unknown frequency (frequency cannot be estimated from available data):
Consult your doctor if you experience weakness in the arms or legs that worsens after periods of activity, double vision, eyelid drooping, difficulty swallowing, or difficulty breathing.
In addition, the following side effects have been reported in people taking ORVATEZ tablets, ezetimibe, or atorvastatin:
Possible side effects reported with some statins
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Medications should not be disposed of through drains or in the trash. Deposit the containers and medications you no longer need at the SIGRE collection point at the pharmacy.Ask your pharmacist how to dispose of the containers and medications you no longer need if you are unsure. By doing so, you will help protect the environment.
The active principles are ezetimiba and atorvastatina. Each film-coated tablet contains 10mg of ezetimiba and 20mg, 40mg or 80mg of atorvastatina (as atorvastatina calcium trihydrate).
The other components are: calcium carbonate;colloidal anhydrous silica; croscarmelosa sodium; hydroxypropylcellulose; lactose monohydrate; magnesium stearate; microcrystalline cellulose; polisorbate 80; povidone; sodium lauryl sulfate.
The coating of the tablet contains: hypromelose, macrogol 8000, titanium dioxide (E-171) and talc.
Appearance of the product and contents of the package
Film-coated tablets, capsule-shaped, biconvex and white to bone-colored.
ORVATEZ 10mg/20mg tablets: with the code “333” on one side
ORVATEZ 10mg/40mg tablets: with the code “337” on one side
ORVATEZ 10mg/80mg tablets: with the code “357” on one side
Package sizes:
Blister packs of 10, 30, 90 and 100 film-coated tablets in aluminium/aluminium (oriented polyamide-aluminium-PVC with aluminium coating).
Unit dose packs of 30 x 1 and 45 x 1 film-coated tablets in aluminium/aluminium (oriented polyamide-aluminium-PVC with aluminium coating).
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Organon Salud, S.L.
Paseo de la Castellana, 77
28046 Madrid
Spain
Phone: 915911279
Responsible manufacturer:
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
Organon Heist bv
Industriepark 30
2220 Heist-op-den-Berg
Belgium
Local representative:
Laboratorios Farmacéuticos ROVI, S.A.
Julián Camarillo, 35 – 28037 Madrid
Spain
This medicinal product is authorized in the member states of the European Economic Area with the following names:
ORVATEZ:Germany, Greece, Italy, Portugal and Spain
TIOBLIS:Belgiumand Luxembourg
Last review date of this leaflet:07/2023.
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.